{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:11:22Z","timestamp":1770887482986,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.heliyon.2022.e12150","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:29:50Z","timestamp":1670380190000},"page":"e12150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia"],"prefix":"10.1016","volume":"8","author":[{"given":"Ye","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-6331","authenticated-orcid":false,"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2022.e12150_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.02.032","article-title":"Incidence of endometrial hyperplasia","volume":"200","author":"Reed","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e12150_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00404-019-05299-2","article-title":"Significant risk of occult cancer in complex non-atypical endometrial hyperplasia","volume":"300","author":"Travaglino","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e12150_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s12253-019-00684-3","article-title":"Diabetes Mellitus is associated with occult cancer in endometrial hyperplasia","volume":"26","author":"Raffone","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.heliyon.2022.e12150_bib4","series-title":"Endometrial Hyperplasia","author":"Singh G","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e12150_bib5","first-page":"127","article-title":"Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest","volume":"3","author":"Bitzer","year":"2011","journal-title":"Int. J. Wom. Health"},{"issue":"9","key":"10.1016\/j.heliyon.2022.e12150_bib6","first-page":"CD012658","article-title":"Levonorgestrel-releasing intrauterine system for endometrial hyperplasia","volume":"9","author":"Mittermeier","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e12150_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.05.029","article-title":"National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia","volume":"221","author":"Harrison","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.heliyon.2022.e12150_bib8","series-title":"NCCN Guidelines","year":"2019"},{"key":"10.1016\/j.heliyon.2022.e12150_bib9","series-title":"Principles and Practice of Gynecologic Oncology","author":"Chi","year":"2017"},{"issue":"20","key":"10.1016\/j.heliyon.2022.e12150_bib10","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J.\u00a0Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"38","key":"10.1016\/j.heliyon.2022.e12150_bib11","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1038\/sj.onc.1207899","article-title":"Prevention of cancers of the breast, endometrium and ovary","volume":"23","author":"Pike","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e12150_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ijc.25050","article-title":"Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition","volume":"127","author":"Dossus","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e12150_bib13","first-page":"271","article-title":"Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?","volume":"5","author":"Rodriguez","year":"1998","journal-title":"J.\u00a0Soc. Gynecol. Invest."},{"issue":"9","key":"10.1016\/j.heliyon.2022.e12150_bib14","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/ijc.33360","article-title":"Pregnancy outcomes and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium","volume":"148","author":"Jordan","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2022.e12150_bib15","doi-asserted-by":"crossref","first-page":"547 e1","DOI":"10.1016\/j.ajog.2010.07.037","article-title":"Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis","volume":"203","author":"Gallos","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e12150_bib16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ajog.2015.03.037","article-title":"Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials","volume":"213","author":"Abu Hashim","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2 Pt 1","key":"10.1016\/j.heliyon.2022.e12150_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/AOG.0b013e3181e93330","article-title":"Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy","volume":"116","author":"Reed","year":"2010","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e12150_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/AOG.0b013e318198a10a","article-title":"Progestin therapy of complex endometrial hyperplasia with and without atypia","volume":"113","author":"Reed","year":"2009","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e12150_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1297-9589(02)00301-6","article-title":"[Endometrial hyperplasias resistant to progestins: alternatives to traditional treatments]","volume":"30","author":"Brun","year":"2002","journal-title":"Gynecol. Obstet. Fertil."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e12150_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1471-0528.12499","article-title":"Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial","volume":"121","author":"Orbo","year":"2014","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e12150_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.maturitas.2006.11.010","article-title":"Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution","volume":"57","author":"Wildemeersch","year":"2007","journal-title":"Maturitas"},{"issue":"11","key":"10.1016\/j.heliyon.2022.e12150_bib22","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/humrep\/det320","article-title":"LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study","volume":"28","author":"Gallos","year":"2013","journal-title":"Hum. Reprod."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e12150_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e12150_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3802\/jgo.2013.24.2.128","article-title":"LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial","volume":"24","author":"Abu Hashim","year":"2013","journal-title":"J.\u00a0Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e12150_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1933719114542014","article-title":"Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia","volume":"22","author":"El Behery","year":"2015","journal-title":"Reprod. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e12150_bib26","first-page":"122","article-title":"The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study","volume":"40","author":"Dolapcioglu","year":"2013","journal-title":"Clin. Exp. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.heliyon.2022.e12150_bib27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/1933719114561553","article-title":"Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia","volume":"22","author":"Bian","year":"2015","journal-title":"Reprod. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022034387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022034387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:43:40Z","timestamp":1767102220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022034387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2405844022034387"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e12150","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e12150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e12150"}}